- Bioidentical
-
Hormones structurally identical to those produced by the body, as opposed to synthetic
analogues; commonly used to describe estrogen and progesterone formulations in HRT that
mirror endogenous hormone chemistry. The term describes molecular structure, not sourcing
or regulatory status.
- BPC-157
-
Body Protection Compound 157 — a peptide studied for tissue repair, gut-lining integrity,
and anti-inflammatory signalling. It is the primary peptide in Eterna Femme's
Recovery & Vitality approaches.
- CJC-1295
-
A growth hormone-releasing hormone analogue that extends the natural GH pulse window
during deep sleep without blunting the body's pulsatile secretion rhythm. It anchors the
Sleep & Restoration approaches.
- Compounding pharmacy
-
A licensed pharmacy that prepares custom medications to a patient's specific prescription
rather than dispensing a mass-manufactured product; the regulatory model under which
clinical-curator-prescribed peptides are prepared to pharmaceutical identity, purity,
and potency standards.
- Epitalon
-
A tetrapeptide studied for its role in telomere elongation and pineal gland regulation;
part of the Longevity & Cellular Health approaches
alongside MOTS-c.
- GLP-1 agonist
-
A class of metabolic peptides and drugs — including semaglutide, tirzepatide, and
retatrutide — that mimic the gut hormone GLP-1 to regulate insulin secretion and
appetite. Retatrutide also agonises GIP and glucagon receptors, making it a triple
agonist.
- Growth hormone (GH)
-
A pituitary hormone governing tissue repair, lean-mass maintenance, and metabolic
signalling; secreted in discrete overnight pulses whose amplitude and frequency decline
with age and are disrupted by the hormonal shifts of perimenopause.
- HPA axis
-
The hypothalamic-pituitary-adrenal axis — the body's central stress-response circuit;
elevated cortisol from HPA over-activation suppresses GH pulsatility, impairs deep
sleep, and accelerates muscle breakdown, making it a core concern in midlife women
managing sleep and recovery.
- HRT / Hormone Replacement Therapy
-
The clinical use of exogenous estrogen and/or progesterone to restore hormonal levels
during perimenopause and postmenopause; it works on different biological pathways than
peptide therapy and is often used alongside rather than instead of a peptide approach.
Read more at Peptides & HRT.
- Mitochondrial efficiency
-
The capacity of cells' energy-producing organelles to generate ATP without excess
oxidative by-product; mitochondrial efficiency declines with age and hormonal shift,
contributing to fatigue and metabolic slowdown that many women first notice in their
late 40s.
- MOTS-c
-
A mitochondria-derived peptide that regulates cellular energy metabolism and has been
studied for insulin-sensitising effects; part of the
Longevity & Cellular Health approaches
alongside Epitalon.
- Peptide therapy
-
The therapeutic use of short amino-acid chains (peptides) to signal specific biological
pathways — tissue repair, GH release, cellular longevity, or metabolic function — as a
targeted research-backed intervention distinct from hormone replacement or general
supplementation.
- Perimenopause
-
The hormonal transition that precedes the final menstrual period, typically beginning
in the mid-to-late 40s; characterised by fluctuating estrogen and progesterone, cycle
irregularity, and symptom patterns — sleep changes, mood shifts, body-composition
change — that may span four to ten years before menopause is reached.
See the perimenopause staging guide.
- Postmenopause
-
The phase beginning 12 months after a woman's final menstrual period, defined by a
sustained low-estrogen baseline; bone-density loss accelerates, metabolic risk shifts,
and the cellular-longevity and bone approaches become the primary areas of focus.
Read the menopause guide.
- Telomere
-
The protective cap at the end of each chromosome that shortens with every cell division;
telomere length is used as a marker of biological aging, and Epitalon has been studied
for its ability to activate telomerase, the enzyme that rebuilds this cap.
- Vasomotor symptoms
-
The cluster of temperature-dysregulation symptoms — hot flashes, night sweats, sudden
chills — driven by hypothalamic thermoregulatory dysfunction as estrogen levels
fluctuate or fall; one of the most common and disruptive symptom groups in
perimenopause.